Aurobindo Pharma Ltd

BSE: 524804 NSE: AUROPHARMA
Aurobindo Pharma Ltd - pharma in Hyderabad, Telangana, India. FY 2026 financials and compliance.
CIN L24239TG1986PLC015190 Incorporated 26 December 1986 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: AUROPHARMA · BSE: 524804 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹33,653 Cr
▲ 6.08% YoY
Computed EBITDA · FY 2026
₹7,337.82 Cr
▲ 1.85% YoY
Net profit · FY 2026
₹3,502.97 Cr
▲ 0.56% YoY
Authorised capital
₹666.4 Cr
Registered with MCA
Paid-up capital
₹57.54 Cr
Issued & subscribed
Open charges
₹2,000 Cr
Satisfied ₹4,387.54 Cr
Company age
40 yrs
Est. 1986
Employees · EPFO
15,925
Latest available

About Aurobindo Pharma Ltd

Data last updated: 14 July 2026

Aurobindo Pharma Ltd is a public limited company based in Hyderabad, Telangana, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 26 December 1986, the company has been in operation for over 40 years.

Registered with ROC Hyderabad under CIN L24239TG1986PLC015190. Listed on BSE: 524804 and NSE: AUROPHARMA.

Capital: an authorised share capital of ₹666.4 Cr and a paid-up capital of ₹57.54 Cr. Formerly known as Aurobindo Pharma Pvt Ltd. It is led by directors including Girish Paman Vanvari and Venkata Ramprasad Reddy Penaka.

Last AGM: 10 September 2025. Financial statements filed for year ended 31 March 2025. Office: Plot No.2 Maithrivihar Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, India – 500038.

As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹33,653 Cr, a growth of 6.08% compared to the previous year. The net worth stands at ₹37,883 Cr (up 16.04% YoY). Total assets are valued at ₹58,502 Cr (up 17.51% YoY).

The company has a workforce of approximately 15,925 employees as per the latest available data. Its group structure includes 17 subsidiaries and 2 joint ventures.

The company is associated with 3 brands - Auronext Pharma, Aurobindo Pharma, Tergene Biotech. As per MCA filings, the company has open charges of ₹2,000 Cr and satisfied charges of ₹4,387.54 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aurobindo.com.

Company Details of Aurobindo Pharma Ltd
CIN L24239TG1986PLC015190
Registration Number 015190
Incorporation Date 26 December 1986
ROC Hyderabad
Listing Status Listed (BSE: 524804, NSE: AUROPHARMA)
Company Status Active
Date of Last AGM 10 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Nityananda Reddy Kambam Managing Director Madan Mohan Reddy Mettu Whole-Time Director Girish Paman Vanvari Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    aurobindo.com
  • Social Media
  • Registered Address
    Plot No.2 Maithrivihar Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, India – 500038
  • Industry
    Pharma, Drug Formulation & Development
Company report
Aurobindo Pharma Ltd - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Aurobindo Pharma Ltd report

Financials, compliance, directors, charges, ownership and filings for Aurobindo Pharma Ltd in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has one previous CIN (Corporate Identification Number): L24239AP1986PLC015190. The current CIN is L24239TG1986PLC015190, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24239TG1986PLC015190 Current
L24239AP1986PLC015190 Previous

Associated Brands with Aurobindo Pharma Ltd

Aurobindo Pharma Ltd operates multiple associated brands including Auronext Pharma, Aurobindo Pharma, and Tergene Biotech. These brands represent Aurobindo Pharma Ltd's diversified market presence and brand portfolio.

Brand Description Website
Aurobindo Pharma
Generic biocatalytic solutions are provided for pharmaceutical applications. aurobindo.com
Tergene Biotech
Bio-conjugate technologies for bacterial vaccines and conjugates are developed. tergene.com
Auronext Pharma
Offers comprehensive outsourced API production services for the pharmaceutical industry. auronext.com

Competitors & Alternatives of Aurobindo Pharma Ltd

Brands and companies operating in the same space as Aurobindo Pharma Ltd include Laurus Labs, Biological E, Concord Biotech and 7 more.

Competitor Description Location Founded
Laurus Labs Laurus Labs Pharmaceutical and biotechnology company Hyderabad, India, India 2005
Biological E Biological E Vaccines and therapeutics for multiple diseases are developed and marketed. Hyderabad, India, India 1953
Concord Biotech Concord Biotech APIs and enzymes are manufactured through fermentation by the CDMO. Ahmedabad, India, India 2000
Symbiotec Symbiotec Non-sterile steroid hormone-based APIs and intermediates are manufactured. Indore, India, India 2002
BDR Pharmaceuticals Internationals BDR Pharmaceuticals Internationals APIs and finished products are developed and manufactured. Mumbai, India, India 2003
Insmed Insmed Developer of small molecule inhibitors for rare lung diseases Bridgewater, United States, United States 1999
Vaxart Vaxart Developer of therapeutic solutions for treating multiple infectious diseases San Francisco, United States, United States 2004
Almac Group Almac Group Integrated CDMO services for biopharma R&D and manufacturing are offered. Craigavon, United Kingdom, United Kingdom 2001
Beijing Biostar Technologies Beijing Biostar Technologies APIs, intermediates, and biochemical reagents are developed and manufactured. Beijing, China, China 2002
Indoco Remedies Indoco Remedies APIs manufacturing and formulation services are provided in therapeutic segments. Mumbai, India, India 1947

Business Activity of Aurobindo Pharma Ltd

Aurobindo Pharma Ltd is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Aurobindo Pharma Ltd

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Aurobindo Pharma Ltd

Aurobindo Pharma Ltd is audited by Deloitte Haskins & Sells (ICAI peer reviewed, certificate valid till 2028-04-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Deloitte Haskins & Sells (ICAI peer reviewed, certificate valid till 2028-04-30) FY 2026 Declaration of unmodified opinion

Board of Directors of Aurobindo Pharma Ltd

Aurobindo Pharma Ltd is currently managed by 9 directors, with 22 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Girish Paman Vanvari
Also directs: Aurobindo Pharma Ltd, Transaction Square Llp, Transaction Square Consultancy Llp and 5 more
Director 05 Nov 2020 5 Years 9 Months Current
Venkata Ramprasad Reddy Penaka
Also directs: Aurobindo Pharma Ltd, Penaka Pharma (India) Private Limited, Rpr Sons Advisors Private Limited
Director 30 Dec 1992 33 Years 7 Months Current
Madan Mohan Reddy Mettu
Also directs: Aurobindo Pharma Ltd, Mss Packaging Industries Llp, Engenra Biologics Private Limited and 5 more
Whole-Time Director 01 Jan 2013 13 Years 7 Months Current
Sarath Chandra Reddy Penaka
Also directs: Aurobindo Pharma Ltd, Aurobindo Pharma Foundation, Sarath Penaka Enterprises Llp and 5 more
Director 27 Sep 2007 18 Years 10 Months Current
Nityananda Reddy Kambam
Also directs: Aurobindo Pharma Ltd, Aurobindo Antibiotics Private Limited, Apl Healthcare Limited and 5 more
Managing Director 30 Dec 1992 33 Years 7 Months Current
Santanu Mukherjee
Also directs: Aurobindo Pharma Ltd, Apitoria Pharma Private Limited, Suven Life Sciences Limited and 5 more
Director 09 Feb 2023 3 Years 6 Months Current
Showing 6 of 9 current directors. View all directors

Financials of Aurobindo Pharma Ltd FY 2026 filings available

Aurobindo Pharma Ltd reported revenue of ₹33,653 Cr (up 6.08% YoY) for FY 2026.

Revenue · FY 2026
₹33,653 Cr ▲ 6.08%
Profit · FY 2026
₹3,502.97 Cr ▲ 0.56%
Computed EBITDA · FY 2026
₹7,337.82 Cr ▲ 1.85%
Revenue₹ Cr · Consolidated020,00040,000FY 2020: ₹23,099 Cr23,098FY 2020FY 2021: ₹24,775 Cr · +7.3% YoY24,775+7.3%FY 2021FY 2022: ₹23,455 Cr · -5.3% YoY23,455-5.3%FY 2022FY 2023: ₹24,855 Cr · +6% YoY24,855+6%FY 2023FY 2024: ₹29,002 Cr · +16.7% YoY29,002+16.7%FY 2024FY 2025: ₹31,724 Cr · +9.4% YoY31,724+9.4%FY 2025FY 2026: ₹33,653 Cr · +6.1% YoY33,653+6.1%FY 2026
Net Profit₹ Cr · Consolidated02,0004,0006,000FY 2020: ₹2,830 Cr2,830FY 2020FY 2021: ₹5,334 Cr · +88.5% YoY5,334+88.5%FY 2021FY 2022: ₹2,647 Cr · -50.4% YoY2,647-50.4%FY 2022FY 2023: ₹1,928 Cr · -27.2% YoY1,928-27.2%FY 2023FY 2024: ₹3,169 Cr · +64.4% YoY3,169+64.4%FY 2024FY 2025: ₹3,484 Cr · +9.9% YoY3,484+9.9%FY 2025FY 2026: ₹3,503 Cr · +0.6% YoY3,503+0.6%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year05,00010,000Q1'25: ₹7,567 Cr · +10.5% YoY7,567+10.5%Q1'25Q2'25: ₹7,796 Cr · +8% YoY7,796+8%Q2'25Q3'25: ₹7,979 Cr · +8.5% YoY7,979+8.5%Q3'25Q4'25: ₹8,382 Cr · +10.6% YoY8,382+10.6%Q4'25Q1'26: ₹7,868 Cr · +4% YoY7,868+4%Q1'26Q2'26: ₹8,286 Cr · +6.3% YoY8,286+6.3%Q2'26Q3'26: ₹8,646 Cr · +8.4% YoY8,646+8.4%Q3'26Q4'26: ₹8,853 Cr · +5.6% YoY8,853+5.6%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹33,653 Cr ₹31,724 Cr ₹29,002 Cr ₹24,855 Cr ₹23,455 Cr ₹24,775 Cr ₹23,099 Cr
Other Income ₹492.09 Cr ₹621.85 Cr ₹557.38 Cr ₹290.59 Cr ₹320.35 Cr ₹380.84 Cr ₹86.2 Cr
Total Income ₹34,145 Cr ₹32,346 Cr ₹29,559 Cr ₹25,146 Cr ₹23,776 Cr ₹25,155 Cr ₹23,185 Cr
Cost of Materials Consumed ₹10,305 Cr ₹10,737 Cr ₹10,776 Cr ₹9,652.51 Cr ₹7,371.83 Cr ₹8,317.27 Cr ₹7,724.98 Cr
Purchases of Stock-in-Trade ₹3,477.98 Cr ₹2,887.11 Cr ₹2,772.93 Cr ₹2,050.43 Cr ₹1,951.77 Cr ₹2,315.42 Cr ₹2,112.11 Cr
Changes in Inventories -₹294.81 Cr -₹597.63 Cr -₹946.17 Cr -₹409.68 Cr ₹816.68 Cr -₹730.21 Cr -₹101.86 Cr
Employee Benefit Expense ₹5,190.17 Cr ₹4,475.62 Cr ₹3,922.94 Cr ₹3,522.25 Cr ₹3,450.92 Cr ₹3,535.02 Cr ₹3,219.18 Cr
Finance Costs ₹383.97 Cr ₹457.24 Cr ₹289.71 Cr ₹140.48 Cr ₹48.64 Cr ₹74.49 Cr ₹159.77 Cr
Depreciation & Amortisation ₹1,778.19 Cr ₹1,649.42 Cr ₹1,521.66 Cr ₹1,244.58 Cr ₹1,126.52 Cr ₹1,055.38 Cr ₹966.71 Cr
Other Expenses ₹8,128.82 Cr ₹7,639.08 Cr ₹6,633.03 Cr ₹6,321.23 Cr ₹5,477.52 Cr ₹6,003.72 Cr ₹5,319.49 Cr
Total Expenses ₹28,970 Cr ₹27,248 Cr ₹24,970 Cr ₹22,522 Cr ₹20,244 Cr ₹20,571 Cr ₹19,400 Cr
Profit Before Exceptional Items & Tax ₹5,175.66 Cr ₹5,097.98 Cr ₹4,589.01 Cr ₹2,624.17 Cr ₹3,531.96 Cr ₹4,584.38 Cr ₹3,784.32 Cr
Exceptional Items -₹65.33 Cr ₹0 -₹191.86 Cr ₹0 -₹127.97 Cr ₹2,814.58 Cr -₹26.13 Cr
Profit Before Tax ₹5,110.33 Cr ₹5,097.98 Cr ₹4,397.15 Cr ₹2,624.17 Cr ₹3,403.99 Cr ₹7,398.96 Cr ₹3,758.19 Cr
Total Tax Expense ₹1,608.88 Cr ₹1,582.72 Cr ₹1,211.02 Cr ₹684.85 Cr ₹725.63 Cr ₹2,009.77 Cr ₹913.51 Cr
Net Profit ₹3,502.97 Cr ₹3,483.57 Cr ₹3,168.97 Cr ₹1,927.65 Cr ₹2,647.11 Cr ₹5,333.83 Cr ₹2,829.51 Cr
  attributable to Owners ₹3,504.75 Cr ₹3,485.88 Cr ₹3,172.97 Cr ₹1,927.5 Cr ₹2,648.15 Cr ₹5,338.58 Cr ₹2,830.97 Cr
  attributable to NCI -₹1.78 Cr -₹2.31 Cr -₹4 Cr ₹15 Lakh -₹1.04 Cr -₹1.02 Cr -₹1.46 Cr
Other Comprehensive Income ₹1,965.2 Cr ₹303.62 Cr ₹99.16 Cr ₹735.58 Cr ₹261.65 Cr ₹4.74 Cr ₹287.12 Cr
Total Comprehensive Income ₹5,468.17 Cr ₹3,787.19 Cr ₹3,268.13 Cr ₹2,663.23 Cr ₹2,908.76 Cr ₹5,338.57 Cr ₹3,116.63 Cr
EBITDA (computed) ₹7,337.82 Cr ₹7,204.64 Cr ₹6,400.38 Cr ₹4,009.23 Cr ₹4,707.12 Cr ₹5,714.25 Cr ₹4,910.8 Cr
Basic EPS ₹60.34 ₹59.81 ₹54.16 ₹32.90 ₹45.19 ₹91.04 ₹48.32
Diluted EPS ₹60.34 ₹59.81 ₹54.16 ₹32.90 ₹45.19 ₹91.04 ₹48.32
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹58,502 Cr ₹49,785 Cr ₹45,072 Cr ₹39,890 Cr
Non-current Assets ₹25,793 Cr ₹22,623 Cr ₹20,866 Cr ₹18,344 Cr
Current Assets ₹32,709 Cr ₹27,162 Cr ₹23,772 Cr ₹21,546 Cr
Property, Plant & Equipment ₹14,330 Cr ₹12,189 Cr ₹11,546 Cr ₹7,995.38 Cr
Inventories ₹12,053 Cr ₹10,544 Cr ₹9,808.23 Cr ₹8,511.23 Cr
Trade Receivables ₹7,094.37 Cr ₹5,745.93 Cr ₹4,816.74 Cr ₹4,466.38 Cr
Cash & Equivalents ₹7,191.4 Cr ₹5,568.95 Cr ₹3,393.48 Cr ₹4,396.29 Cr
Equity (Net Worth) ₹37,883 Cr ₹32,647 Cr ₹29,851 Cr ₹26,852 Cr
Equity Share Capital ₹58.08 Cr ₹58.08 Cr ₹58.59 Cr ₹58.59 Cr
Borrowings (Non-current) ₹802.75 Cr ₹1,561.65 Cr ₹2,134.9 Cr ₹618.96 Cr
Borrowings (Current) ₹6,873.45 Cr ₹6,380.03 Cr ₹4,180.32 Cr ₹4,242.56 Cr
Total Debt (computed) ₹7,676.2 Cr ₹7,941.68 Cr ₹6,315.22 Cr ₹4,861.52 Cr
Current Liabilities ₹18,039 Cr ₹14,682 Cr ₹12,199 Cr ₹11,494 Cr
Total Liabilities ₹20,619 Cr ₹17,138 Cr ₹15,221 Cr ₹13,038 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹5,526.37 Cr ₹3,924.62 Cr ₹2,434.52 Cr ₹2,386.75 Cr ₹5,016.48 Cr
Investing Cash Flow -₹3,458.43 Cr -₹1,875.14 Cr -₹4,255.95 Cr -₹3,977.75 Cr -₹3,214.81 Cr
Financing Cash Flow -₹1,269.15 Cr ₹119.78 Cr ₹800.42 Cr ₹1,814.41 Cr -₹2,969.27 Cr
Capital Expenditure ₹2,685.77 Cr ₹1,967.86 Cr ₹2,780.33 Cr ₹2,403.8 Cr ₹2,052.91 Cr
Free Cash Flow (computed) ₹2,840.6 Cr ₹1,956.76 Cr -₹345.81 Cr -₹17.05 Cr ₹2,963.57 Cr
Dividends Paid ₹232.4 Cr ₹0 ₹263.64 Cr ₹439.53 Cr ₹263.7 Cr
Net Change in Cash ₹1,627.61 Cr ₹2,178.36 Cr -₹1,006.84 Cr ₹223.35 Cr -₹1,167.4 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹8,853.34 Cr ₹8,645.9 Cr ₹8,285.7 Cr ₹7,868.14 Cr ₹8,382.12 Cr ₹7,978.52 Cr ₹7,796.07 Cr ₹7,567.02 Cr ₹7,580.15 Cr ₹7,351.78 Cr ₹7,219.42 Cr ₹6,850.52 Cr
Other Income ₹117.04 Cr ₹187.64 Cr ₹120.59 Cr ₹105.3 Cr ₹134.81 Cr ₹157.29 Cr ₹136 Cr ₹220.93 Cr ₹135.62 Cr ₹162.52 Cr ₹186.98 Cr ₹116.33 Cr
Total Income ₹8,970.38 Cr ₹8,833.54 Cr ₹8,406.29 Cr ₹7,973.44 Cr ₹8,516.93 Cr ₹8,135.81 Cr ₹7,932.07 Cr ₹7,787.95 Cr ₹7,715.77 Cr ₹7,514.3 Cr ₹7,406.4 Cr ₹6,966.85 Cr
Cost of Materials Consumed ₹2,505.35 Cr ₹2,754.88 Cr ₹2,509.8 Cr ₹2,535.16 Cr ₹2,799.51 Cr ₹2,728.74 Cr ₹2,741.85 Cr ₹2,466.66 Cr ₹2,634.88 Cr ₹2,675.52 Cr ₹2,708.91 Cr ₹2,756.83 Cr
Purchases of Stock-in-Trade ₹931.48 Cr ₹892.65 Cr ₹846.05 Cr ₹807.8 Cr ₹636.18 Cr ₹823.89 Cr ₹747.03 Cr ₹680.01 Cr ₹785.95 Cr ₹775.75 Cr ₹631.07 Cr ₹580.16 Cr
Changes in Inventories -₹7.76 Cr -₹166.32 Cr -₹16.99 Cr -₹103.74 Cr -₹7.81 Cr -₹237.22 Cr -₹278.61 Cr -₹73.99 Cr -₹359.95 Cr -₹300.7 Cr -₹103.24 Cr -₹182.28 Cr
Employee Benefit Expense ₹1,373.98 Cr ₹1,310.06 Cr ₹1,277.33 Cr ₹1,228.8 Cr ₹1,162.64 Cr ₹1,131.55 Cr ₹1,109.48 Cr ₹1,071.95 Cr ₹1,026.32 Cr ₹989.68 Cr ₹954.97 Cr ₹951.97 Cr
Finance Costs ₹98.21 Cr ₹92.77 Cr ₹95.24 Cr ₹97.75 Cr ₹115.02 Cr ₹118.48 Cr ₹112.7 Cr ₹111.04 Cr ₹89.43 Cr ₹75.55 Cr ₹68.18 Cr ₹56.55 Cr
Depreciation & Amortisation ₹478.57 Cr ₹464.73 Cr ₹429.19 Cr ₹405.7 Cr ₹444.43 Cr ₹418.53 Cr ₹382.28 Cr ₹404.18 Cr ₹354.33 Cr ₹423.27 Cr ₹417.5 Cr ₹326.56 Cr
Other Expenses ₹2,297.51 Cr ₹2,081.29 Cr ₹1,991.41 Cr ₹1,797.09 Cr ₹1,999.68 Cr ₹1,953.58 Cr ₹1,910.18 Cr ₹1,802.82 Cr ₹1,820.14 Cr ₹1,610.22 Cr ₹1,654.27 Cr ₹1,592.47 Cr
Total Expenses ₹7,677.34 Cr ₹7,430.06 Cr ₹7,132.03 Cr ₹6,768.56 Cr ₹7,149.65 Cr ₹6,937.55 Cr ₹6,724.91 Cr ₹6,462.67 Cr ₹6,351.1 Cr ₹6,249.29 Cr ₹6,331.66 Cr ₹6,082.26 Cr
Profit Before Exceptional Items & Tax ₹1,293.04 Cr ₹1,403.48 Cr ₹1,274.26 Cr ₹1,204.88 Cr ₹1,367.28 Cr ₹1,198.26 Cr ₹1,207.16 Cr ₹1,325.28 Cr ₹1,364.67 Cr ₹1,265.01 Cr ₹1,074.74 Cr ₹884.59 Cr
Exceptional Items ₹0 -₹65.33 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 -₹122.11 Cr ₹0 ₹0 -₹69.75 Cr
Profit Before Tax ₹1,293.04 Cr ₹1,338.15 Cr ₹1,274.26 Cr ₹1,204.88 Cr ₹1,367.28 Cr ₹1,198.26 Cr ₹1,207.16 Cr ₹1,325.28 Cr ₹1,242.56 Cr ₹1,265.01 Cr ₹1,074.74 Cr ₹814.84 Cr
Total Tax Expense ₹369.77 Cr ₹428.72 Cr ₹427.79 Cr ₹382.6 Cr ₹432.26 Cr ₹354.28 Cr ₹390.51 Cr ₹405.67 Cr ₹322.55 Cr ₹322.45 Cr ₹323.7 Cr ₹242.32 Cr
Net Profit ₹920.84 Cr ₹909.8 Cr ₹848.13 Cr ₹824.2 Cr ₹902.83 Cr ₹845.57 Cr ₹816.95 Cr ₹918.22 Cr ₹907.35 Cr ₹939.97 Cr ₹751.94 Cr ₹569.71 Cr
  attributable to Owners ₹921.26 Cr ₹910.29 Cr ₹848.45 Cr ₹824.75 Cr ₹903.47 Cr ₹854.81 Cr ₹817.38 Cr ₹919.22 Cr ₹908.75 Cr ₹936.29 Cr ₹757.18 Cr ₹570.75 Cr
  attributable to NCI -₹42 Lakh -₹49 Lakh -₹32 Lakh -₹55 Lakh -₹64 Lakh -₹24 Lakh -₹43 Lakh -₹1 Cr -₹1.4 Cr ₹3.68 Cr -₹5.24 Cr -₹1.04 Cr
Other Comprehensive Income ₹790.56 Cr ₹227.73 Cr ₹541.07 Cr ₹405.84 Cr ₹139.66 Cr -₹65.27 Cr ₹270.28 Cr -₹41.05 Cr -₹110.57 Cr ₹188.7 Cr ₹51.4 Cr -₹30.37 Cr
Total Comprehensive Income ₹1,711.4 Cr ₹1,137.53 Cr ₹1,389.2 Cr ₹1,230.04 Cr ₹1,042.49 Cr ₹780.3 Cr ₹1,087.23 Cr ₹877.17 Cr ₹796.78 Cr ₹1,128.67 Cr ₹803.34 Cr ₹539.34 Cr
EBITDA (computed) ₹1,869.82 Cr ₹1,960.98 Cr ₹1,798.69 Cr ₹1,708.33 Cr ₹1,926.73 Cr ₹1,735.27 Cr ₹1,702.14 Cr ₹1,840.5 Cr ₹1,808.43 Cr ₹1,763.83 Cr ₹1,560.42 Cr ₹1,267.7 Cr
Basic EPS ₹15.86 ₹15.67 ₹14.61 ₹14.20 ₹15.56 ₹14.56 ₹14.00 ₹15.69 ₹15.51 ₹16.04 ₹12.83 ₹9.74
Diluted EPS ₹15.86 ₹15.67 ₹14.61 ₹14.20 ₹15.56 ₹14.56 ₹14.00 ₹15.69 ₹15.51 ₹16.04 ₹12.83 ₹9.74
Latest 12 quarters shown of 25 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹11,172 Cr ₹10,933 Cr ₹10,646 Cr ₹12,792 Cr ₹11,287 Cr ₹15,824 Cr ₹13,266 Cr
Other Income ₹587.53 Cr ₹328.12 Cr ₹616.06 Cr ₹433.76 Cr ₹670.99 Cr ₹589.86 Cr ₹258.01 Cr
Total Income ₹11,759 Cr ₹11,261 Cr ₹11,262 Cr ₹13,226 Cr ₹11,958 Cr ₹16,414 Cr ₹13,524 Cr
Cost of Materials Consumed ₹5,238.38 Cr ₹5,610.21 Cr ₹5,761.08 Cr ₹7,247.69 Cr ₹5,783.93 Cr ₹7,215.73 Cr ₹6,747.55 Cr
Purchases of Stock-in-Trade ₹73.2 Cr ₹65.13 Cr ₹203.4 Cr ₹89.23 Cr ₹16.81 Cr ₹26.09 Cr ₹5.51 Cr
Changes in Inventories ₹46.55 Cr -₹67.66 Cr -₹116.23 Cr -₹466 Cr ₹45.51 Cr ₹2.99 Cr -₹229.53 Cr
Employee Benefit Expense ₹1,161.15 Cr ₹1,063.07 Cr ₹980.56 Cr ₹1,641.88 Cr ₹1,600.04 Cr ₹1,735.43 Cr ₹1,561.47 Cr
Finance Costs ₹213.15 Cr ₹230.04 Cr ₹182.6 Cr ₹114.98 Cr ₹16.94 Cr ₹28.68 Cr ₹95.58 Cr
Depreciation & Amortisation ₹285.36 Cr ₹297.2 Cr ₹254.58 Cr ₹435.35 Cr ₹415.26 Cr ₹487.99 Cr ₹470.48 Cr
Other Expenses ₹1,560.5 Cr ₹1,704.98 Cr ₹1,592.79 Cr ₹2,548.56 Cr ₹2,367.45 Cr ₹2,723.62 Cr ₹2,495.73 Cr
Total Expenses ₹8,578.29 Cr ₹8,902.97 Cr ₹8,858.78 Cr ₹11,612 Cr ₹10,246 Cr ₹12,221 Cr ₹11,147 Cr
Profit Before Exceptional Items & Tax ₹3,180.96 Cr ₹2,358.45 Cr ₹2,402.92 Cr ₹1,614.35 Cr ₹1,712.19 Cr ₹4,193.01 Cr ₹2,377.7 Cr
Exceptional Items -₹17.38 Cr ₹0 ₹0 ₹0 -₹74.71 Cr ₹0 ₹0
Profit Before Tax ₹3,163.58 Cr ₹2,358.45 Cr ₹2,402.92 Cr ₹1,614.35 Cr ₹1,637.48 Cr ₹4,193.01 Cr ₹2,377.7 Cr
Total Tax Expense ₹748.78 Cr ₹611.66 Cr ₹502.82 Cr ₹383.94 Cr ₹182.77 Cr ₹1,080.1 Cr ₹504.96 Cr
Net Profit ₹2,414.8 Cr ₹1,746.79 Cr ₹1,954.14 Cr ₹1,230.41 Cr ₹1,454.71 Cr ₹3,112.91 Cr ₹1,872.74 Cr
Other Comprehensive Income ₹1.08 Cr -₹5.26 Cr -₹1.69 Cr ₹5.87 Cr ₹1.69 Cr -₹6.42 Cr -₹12.55 Cr
Total Comprehensive Income ₹2,415.88 Cr ₹1,741.53 Cr ₹1,952.45 Cr ₹1,236.28 Cr ₹1,456.4 Cr ₹3,106.49 Cr ₹1,860.19 Cr
EBITDA (computed) ₹3,679.47 Cr ₹2,885.69 Cr ₹2,840.1 Cr ₹2,164.68 Cr ₹2,144.39 Cr ₹4,709.68 Cr ₹2,943.76 Cr
Basic EPS ₹41.58 ₹29.97 ₹32.43 ₹21.00 ₹24.83 ₹53.13 ₹31.96
Diluted EPS ₹41.58 ₹29.97 ₹32.43 ₹21.00 ₹24.83 ₹53.13 ₹31.96
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹29,279 Cr ₹27,513 Cr ₹25,154 Cr ₹24,934 Cr
Non-current Assets ₹21,258 Cr ₹19,824 Cr ₹17,915 Cr ₹15,210 Cr
Current Assets ₹8,021.88 Cr ₹7,689.4 Cr ₹7,239.13 Cr ₹9,723.64 Cr
Property, Plant & Equipment ₹2,419.93 Cr ₹2,185.29 Cr ₹2,222.21 Cr ₹3,481.88 Cr
Inventories ₹2,360.57 Cr ₹2,359.28 Cr ₹2,367.6 Cr ₹4,125.26 Cr
Trade Receivables ₹4,209.68 Cr ₹4,195.05 Cr ₹3,776.59 Cr ₹4,560.26 Cr
Cash & Equivalents ₹160.43 Cr ₹295.26 Cr ₹83.32 Cr ₹129.65 Cr
Equity (Net Worth) ₹22,718 Cr ₹20,534 Cr ₹19,723 Cr ₹17,914 Cr
Equity Share Capital ₹58.08 Cr ₹58.08 Cr ₹58.59 Cr ₹58.59 Cr
Borrowings (Non-current) ₹0 ₹400 Cr ₹0 ₹0
Borrowings (Current) ₹4,182.47 Cr ₹4,225.09 Cr ₹2,817.84 Cr ₹4,142.57 Cr
Total Debt (computed) ₹4,182.47 Cr ₹4,625.09 Cr ₹2,817.84 Cr ₹4,142.57 Cr
Current Liabilities ₹6,299.35 Cr ₹6,420.5 Cr ₹5,244.74 Cr ₹6,673.35 Cr
Total Liabilities ₹6,561.69 Cr ₹6,978.95 Cr ₹5,431.16 Cr ₹7,019.48 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹2,933.02 Cr ₹1,645.79 Cr ₹1,714.8 Cr ₹1,821.16 Cr ₹3,726.71 Cr
Investing Cash Flow -₹2,024.96 Cr -₹2,065.9 Cr -₹159.96 Cr -₹3,459.68 Cr -₹1,613.51 Cr
Financing Cash Flow -₹1,072.35 Cr ₹616.31 Cr -₹1,837.03 Cr ₹1,719.48 Cr -₹2,447.54 Cr
Capital Expenditure ₹520.61 Cr ₹246.94 Cr ₹417.59 Cr ₹353.75 Cr ₹614.06 Cr
Free Cash Flow (computed) ₹2,412.41 Cr ₹1,398.85 Cr ₹1,297.21 Cr ₹1,467.41 Cr ₹3,112.65 Cr
Dividends Paid ₹232.4 Cr ₹54 Lakh ₹263.64 Cr ₹439.53 Cr ₹263.7 Cr
Net Change in Cash -₹134.83 Cr ₹211.94 Cr -₹273.81 Cr ₹81.44 Cr -₹335.37 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹2,786.55 Cr ₹2,747.28 Cr ₹2,789.72 Cr ₹2,848.17 Cr ₹2,731.99 Cr ₹2,916.63 Cr ₹2,824.59 Cr ₹2,460.09 Cr ₹2,894.03 Cr ₹2,692.03 Cr ₹2,668.76 Cr ₹2,390.82 Cr
Other Income ₹214.09 Cr ₹130.15 Cr ₹159.52 Cr ₹83.77 Cr ₹113.98 Cr ₹54.26 Cr ₹122.66 Cr ₹65.32 Cr ₹122.97 Cr ₹331.13 Cr ₹67.08 Cr ₹94.88 Cr
Total Income ₹3,000.64 Cr ₹2,877.43 Cr ₹2,949.24 Cr ₹2,931.94 Cr ₹2,845.97 Cr ₹2,970.89 Cr ₹2,947.25 Cr ₹2,525.41 Cr ₹3,017 Cr ₹3,023.16 Cr ₹2,735.84 Cr ₹2,485.7 Cr
Cost of Materials Consumed ₹1,251.66 Cr ₹1,402.55 Cr ₹1,244.16 Cr ₹1,340.01 Cr ₹1,360.7 Cr ₹1,506.59 Cr ₹1,424.74 Cr ₹1,318.18 Cr ₹1,401.56 Cr ₹1,465.93 Cr ₹1,518.33 Cr ₹1,375.26 Cr
Purchases of Stock-in-Trade ₹16.52 Cr ₹20.15 Cr ₹22.15 Cr ₹14.38 Cr ₹16.31 Cr ₹19.06 Cr ₹16.16 Cr ₹13.6 Cr ₹17.01 Cr ₹155.09 Cr ₹15.77 Cr ₹15.53 Cr
Changes in Inventories ₹42.79 Cr -₹135.99 Cr ₹101.27 Cr ₹38.48 Cr ₹60.52 Cr -₹61.37 Cr -₹31.25 Cr -₹35.56 Cr -₹13.1 Cr -₹59.76 Cr -₹27.12 Cr -₹16.25 Cr
Employee Benefit Expense ₹292.71 Cr ₹291.1 Cr ₹294.37 Cr ₹282.97 Cr ₹273.11 Cr ₹265.15 Cr ₹265.48 Cr ₹259.33 Cr ₹248.91 Cr ₹248.08 Cr ₹247.51 Cr ₹236.06 Cr
Finance Costs ₹47.27 Cr ₹48.43 Cr ₹57.45 Cr ₹60 Cr ₹61.09 Cr ₹66.19 Cr ₹51.63 Cr ₹51.13 Cr ₹53.07 Cr ₹61.25 Cr ₹36.69 Cr ₹31.59 Cr
Depreciation & Amortisation ₹71.93 Cr ₹71.92 Cr ₹71.49 Cr ₹70.02 Cr ₹93.88 Cr ₹68.28 Cr ₹68.16 Cr ₹66.88 Cr ₹64.81 Cr ₹64.35 Cr ₹65.79 Cr ₹59.63 Cr
Other Expenses ₹401.45 Cr ₹379.99 Cr ₹403.07 Cr ₹375.99 Cr ₹424.84 Cr ₹474.05 Cr ₹428.58 Cr ₹405.61 Cr ₹464.86 Cr ₹401 Cr ₹369.09 Cr ₹357.84 Cr
Total Expenses ₹2,124.33 Cr ₹2,078.15 Cr ₹2,193.96 Cr ₹2,181.85 Cr ₹2,290.45 Cr ₹2,337.95 Cr ₹2,223.5 Cr ₹2,079.17 Cr ₹2,237.12 Cr ₹2,335.94 Cr ₹2,226.06 Cr ₹2,059.66 Cr
Profit Before Exceptional Items & Tax ₹876.31 Cr ₹799.28 Cr ₹755.28 Cr ₹750.09 Cr ₹555.52 Cr ₹632.94 Cr ₹723.75 Cr ₹446.24 Cr ₹779.88 Cr ₹687.22 Cr ₹509.78 Cr ₹426.04 Cr
Exceptional Items ₹0 -₹17.38 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹876.31 Cr ₹781.9 Cr ₹755.28 Cr ₹750.09 Cr ₹555.52 Cr ₹632.94 Cr ₹723.75 Cr ₹446.24 Cr ₹779.88 Cr ₹687.22 Cr ₹509.78 Cr ₹426.04 Cr
Total Tax Expense ₹184.08 Cr ₹199.83 Cr ₹173.91 Cr ₹190.96 Cr ₹147.35 Cr ₹160.89 Cr ₹186.22 Cr ₹117.2 Cr ₹201.21 Cr ₹63.44 Cr ₹130.13 Cr ₹108.04 Cr
Net Profit ₹692.23 Cr ₹582.07 Cr ₹581.37 Cr ₹559.13 Cr ₹408.17 Cr ₹472.05 Cr ₹537.53 Cr ₹329.04 Cr ₹578.67 Cr ₹623.78 Cr ₹415.74 Cr ₹335.95 Cr
Other Comprehensive Income ₹3.62 Cr -₹1.19 Cr -₹3 Lakh -₹1.32 Cr -₹91 Lakh -₹1.45 Cr -₹2.48 Cr -₹42 Lakh -₹36 Lakh -₹29 Lakh -₹2.51 Cr ₹1.47 Cr
Total Comprehensive Income ₹695.85 Cr ₹580.88 Cr ₹581.34 Cr ₹557.81 Cr ₹407.26 Cr ₹470.6 Cr ₹535.05 Cr ₹328.62 Cr ₹578.31 Cr ₹623.49 Cr ₹413.23 Cr ₹337.42 Cr
EBITDA (computed) ₹995.51 Cr ₹919.63 Cr ₹884.22 Cr ₹880.11 Cr ₹710.49 Cr ₹767.41 Cr ₹843.54 Cr ₹564.25 Cr ₹897.76 Cr ₹812.82 Cr ₹612.26 Cr ₹517.26 Cr
Basic EPS ₹11.92 ₹10.02 ₹10.01 ₹9.63 ₹7.03 ₹8.13 ₹9.21 ₹5.62 ₹9.88 ₹10.65 ₹6.48 ₹5.43
Diluted EPS ₹11.92 ₹10.02 ₹10.01 ₹9.63 ₹7.03 ₹8.13 ₹9.21 ₹5.62 ₹9.88 ₹10.65 ₹6.48 ₹5.43
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Aurobindo Pharma Ltd. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Aurobindo Pharma Ltd

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 51.82%, foreign institutional investors hold 15.24%, domestic institutional investors hold 25.87%, retail and other public shareholders hold 7.08% of Aurobindo Pharma Ltd. The company had 241,298 shareholders on record.

Promoters: 51.82%DII (Domestic Institutional): 25.87%FII (Foreign Institutional): 15.24%Retail & Others: 7.08%
Mar 2026
QUARTER
51.82% Promoters
25.87% DII (Domestic Institutional)
15.24% FII (Foreign Institutional)
7.08% Retail & Others
Promoter holding - history
Now 51.82% · Mar 2026High 53.90% · Dec 2015Low 51.80% · Jun 2024
50%51.3%52.5%53.8%55%Dec 2015Jun 2018Dec 2020Jun 2023Dec 2025Dec 2015: 53.90%Mar 2016: 53.79%Jun 2016: 53.79%Sep 2016: 53.79%Dec 2016: 51.94%Mar 2017: 51.87%Jun 2017: 51.87%Sep 2017: 51.87%Dec 2017: 51.87%Mar 2018: 51.87%Jun 2018: 51.87%Sep 2018: 51.87%Dec 2018: 51.87%Mar 2019: 51.87%Jun 2019: 51.87%Sep 2019: 51.87%Dec 2019: 51.87%Mar 2020: 52.01%Jun 2020: 52.01%Sep 2020: 52.01%Dec 2020: 51.94%Mar 2021: 51.94%Jun 2021: 51.83%Sep 2021: 51.83%Dec 2021: 51.83%Mar 2022: 51.83%Jun 2022: 51.83%Sep 2022: 51.83%Dec 2022: 51.83%Mar 2023: 51.83%Jun 2023: 51.83%Sep 2023: 51.83%Dec 2023: 51.83%Mar 2024: 51.83%Jun 2024: 51.80%Sep 2024: 51.82%Dec 2024: 51.82%Mar 2025: 51.82%Jun 2025: 51.82%Sep 2025: 51.82%Dec 2025: 51.82%Mar 2026: 51.82%53.90%51.80%51.82%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters51.82%51.82%51.82%51.82%51.82%51.82%
Public48.18%48.18%48.18%48.18%48.18%48.18%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters51.82%51.82%51.83%51.83%51.83%51.94%52.01%51.87%51.87%51.87%53.79%
Public48.18%48.18%48.17%48.17%48.17%48.06%47.99%48.13%48.13%48.13%46.21%
Promoter change (YoY, %pts)+0.00-0.01+0.00+0.00-0.11-0.07+0.14+0.00+0.00-1.92-

Board & Governance of Aurobindo Pharma Ltd

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Aurobindo Pharma Ltd has 10 directors - 5 independent and 2 executive. The board is chaired by Mangalam Ramasubramanian Kumar.

DirectorPositionOn board sinceListed boards
Mangalam Ramasubramanian Kumar Non-Executive - Independent Director · Chairperson 2024-04-01 3
Nithyananda Reddy Kambam Executive Director · MD 1986-12-26 1
Madan Mohan Reddy Mettu Executive Director 2006-09-18 1
Venkata Ramprasad Reddy Penaka Non-Executive - Non Independent Director 1986-12-26 1
Sarath Chandra Reddy Penaka Non-Executive - Non Independent Director 2007-09-27 1
Girish Paman Vanvari Non-Executive - Independent Director 2020-11-05 6
Santanu Mukherjee Non-Executive - Independent Director 2023-02-09 4
Satakarni Makkapati Non-Executive - Non Independent Director 2023-11-09 1
Deepali Pant Joshi Non-Executive - Independent Director 2024-02-10 3
Punita Kumar Sinha Non-Executive - Independent Director 2026-02-09 5
Board Committees
CommitteeMembers
Audit Committee Girish Paman Vanvari (Chairperson), Santanu Mukherjee, Nithyananda Reddy Kambam, Punita Kumar Sinha
Nomination and remuneration committee Santanu Mukherjee (Chairperson), Girish Paman Vanvari, Deepali Pant Joshi, Mangalam Ramasubramanian Kumar, Satakarni Makkapati, Punita Kumar Sinha
Stakeholders Relationship Committee Santanu Mukherjee (Chairperson), Nithyananda Reddy Kambam, Girish Paman Vanvari, Mangalam Ramasubramanian Kumar, Deepali Pant Joshi
Risk Management Committee Girish Paman Vanvari (Chairperson), Santanu Mukherjee, Madan Mohan Reddy Mettu
Corporate Social Responsibility Committee Nithyananda Reddy Kambam (Chairperson), Sarath Chandra Reddy Penaka, Girish Paman Vanvari, Deepali Pant Joshi, Mangalam Ramasubramanian Kumar

Group Structure of Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has 17 subsidiary companies, 2 joint ventures, and 2 associated companies. This group structure data is as of FY 2024. The corporate group structure reflects Aurobindo Pharma Ltd's business expansion strategy and organizational complexity.

17
Subsidiary companies
2
Joint ventures
2
Associated companies
Key Subsidiaries
Company Name CIN Shares Held
Aurobindo Antibiotics Private Limited U24110AP2020PTC115965 -
Curateq Biologics Private Limited U24110TG2020PTC140190 -
Auroactive Pharma Private Limited U24230TG2020PTC138313 -
Theranym Biologics Private Limited U24230TG2022PTC166946 -
Auro Peptides Limited U24232TG2012PLC078350 -
Apl Healthcare Limited U24239TG2006PLC052053 -

Showing major subsidiaries. Total: 17.

Charges & Borrowings of Aurobindo Pharma Ltd

Open charges
₹2,000 Cr
Satisfied charges
₹4,387.54 Cr
Breakdown by lending institutions
State Bank of India₹2,000.00 Cr
Latest charge details
DateLenderAmountStatus
05 Jun 1997 State Bank of India ₹2,000 Cr Open
08 Jan 2013 Dbs Bank Ltd ₹164 Cr Satisfied
25 May 2012 Ifci Limited ₹156 Cr Satisfied
25 May 2012 Ifci Limited ₹130 Cr Satisfied
28 Feb 2011 Axis Bank Limited ₹37.98 Cr Satisfied

Total charge records: 44 View all charges

Employees and EPFO Compliance at Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has a workforce of 15,925 employees as of Aug 07, 2024.

Employee count
15,925
Active EPFO establishments
11
Employee growth
-3.17%
Premium access

Employee and EPFO history for Aurobindo Pharma Ltd

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Aurobindo Pharma Ltd

Premium access

GST registrations and filing compliance for Aurobindo Pharma Ltd

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Aurobindo Pharma Ltd

Premium access

Credit ratings, litigation, and regulatory alerts for Aurobindo Pharma Ltd

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Aurobindo Pharma Ltd

Premium access

MSME payment history for Aurobindo Pharma Ltd

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Aurobindo Pharma Ltd

Premium access

Corporate group structure for Aurobindo Pharma Ltd

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Aurobindo Pharma Ltd

Premium access

MCA filings and documents for Aurobindo Pharma Ltd

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Aurobindo Pharma Ltd

Directors
09 Feb 2026
Punita Kumar Sinha was appointed as a Director on 09 Feb 2026 & has been associated with this company since 6 months 9 days.
Activity
10 Sep 2025
Aurobindo Pharma Ltd last Annual general meeting of members was held on 10 Sep 2025 as per latest MCA records.
Activity
31 Mar 2025
Aurobindo Pharma Ltd has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Directors
01 Apr 2024
Mangalam Ramasubramanian Kumar was appointed as a Director on 01 Apr 2024 & has been associated with this company since 2 years 4 months.
Directors
09 Nov 2023
Satakarni Makkapati was appointed as a Director on 09 Nov 2023 & has been associated with this company since 2 years 9 months.
Charges
22 Feb 2023
A charge with State Bank Of India of Rs. 2,000.00 Cr registered on 05 Jun 1997 with Charge ID 80013576 was modified on 22 Feb 2023.

Recent News on Aurobindo Pharma Ltd

Frequently Asked Questions about Aurobindo Pharma Ltd

Aurobindo Pharma Ltd is an active public limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 26 December 1986 (40+ years old) and is registered under CIN L24239TG1986PLC015190. Listed on BSE: 524804 and NSE: AUROPHARMA. The company has 15,925 employees.

Aurobindo Pharma Ltd reported revenue of ₹33,653 Cr for FY 2026 (up 6.08% YoY) based on consolidated NSE filings.

The current directors of Aurobindo Pharma Ltd are:

The primary industry of Aurobindo Pharma Ltd is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Aurobindo Pharma Ltd is listed on both BSE (code: 524804) and NSE (symbol: AUROPHARMA).

Aurobindo Pharma Ltd can be reached at the registered office: Plot No.2 Maithrivihar Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, India – 500038, or through the website aurobindo.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available